Summit Therapeutics Agrees to Sell Antibiotic Ridinilazole to Biossil for Up to $105 Million
Summit Therapeutics (SMMT) has entered into an agreement with Canadian drug developer Biossil to sell its Phase 3 antibiotic candidate, ridinilazole. The deal is valued at up to $105 million and could provide a significant financial boost for Summit.
Tickers: $SMMT
Topics: M&A/licensing deals pharmaceuticals Phase 3 drug development